SCHEMBL25136292

SCHEMBL25136292

COC(=O)c1cc(OC)cc(-c2cncs2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
DYRK1A Q13627 1/20 0.40
BACE1 P56817 1/20 0.39
KMT2A Q03164 1/20 0.39
SCN2A Q99250 1/20 0.39
SCN10A Q9Y5Y9 1/20 0.39
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
HSD17B10 Q99714 2/20 0.37
USP2 O75604 1/20 0.37
IMPDH2 P12268 1/20 0.37
IMPDH1 P20839 1/20 0.37
CD38 P28907 4/20 0.36
HPGD P15428 2/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MYC P01106 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25136274 0.88 MCL1 (0.43) ALDH1A1KMT2ASCN2ASCN10AHSD17B10
SCHEMBL25136290 0.78 WNT1 (0.37) DYRK1AIMPDH2IMPDH1CD38HPGD
SCHEMBL2973753 0.75 BACE1 (0.49) ALDH1A1BACE1KMT2AHPGDKDM4E
SCHEMBL25136226 0.74 SCN2A (0.44) KMT2ASCN2ASCN10AHSD17B10USP2
SCHEMBL25136381 0.72 CD38 (0.45) ALDH1A1HSD17B10CD38HPGDPOLB
SCHEMBL2088551 0.71 CYP3A4 (0.45) ALDH1A1BACE1HSD17B10HPGDKDM4E
SCHEMBL28723091 0.71 MEN1 (0.42) ALDH1A1KMT2ACD38HPGDPOLB
SCHEMBL25485479 0.71 CD38 (0.36) ALDH1A1DYRK1AKMT2AIMPDH2IMPDH1
SCHEMBL11157943 0.70 ACHE (0.47) ALDH1A1HSD17B10HPGDSMN1; SMN2KDM4E
SCHEMBL28724420 0.70 CD38 (0.39) ALDH1A1KMT2AIMPDH2IMPDH1CD38

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4370512-A1 CD38 MODULATORS AND METHODS OF USE THEREOF Cytokinetics, Inc. (US) 2024-05-22 EP disclosed
CN-117813296-A CD38 modulators and methods of use thereof 赛特凯恩蒂克公司 2024-04-02 CN disclosed
US-20230116972-A1 CD38 MODULATORS AND METHODS OF USE THEREOF CYTOKINETICS, INC. 2023-04-20 US disclosed
WO-2023288195-A1 CD38 MODULATORS AND METHODS OF USE THEREOF CYTOKINETICS, INC. (US) 2023-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230116972-A1 CD38 MODULATORS AND METHODS OF USE THEREOF CD38, CXCR4, FCGRT ALDH1A1 358/4885DYRK1A 1430/4885BACE1 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.